Mayo Clinic

The test will leverage next-generation sequencing to sequence PCR amplicons of the UL54 and UL97 genes in which drug resistance with CMV has been associated.

The test covers 27 genes in which variants are known to contribute to the effectiveness or safety of more than 360 medications for 30 conditions.

The firm will use the financing to commercialize a test that utilizes metabolomic and DNA biomarkers to characterize obesity and guide weight loss.

The projects are organized by the Eliminate Cancer Initiative, the National Brain Tumor Society, and the Pediatric Brain Tumor Foundation.

An analysis of matched tumor-normal samples from dozens of colorectal cancer patients pointed to microbiome differences related to mutations and other tumor features.

Mayo Clinic researchers found that cytogenetic subtypes containing three translocations were more common in individuals with a greater proportion of African ancestry.